Two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to…
Based on guidance from biomarker screening, patients who are 55 years of age and older…
Immunotherapy has had limited success so far against glioblastoma, the most common and aggressive form…
Recent research led by MD Anderson identified associations between neoadjuvant immune checkpoint blockade responses and B…
Use of high-dose ifosfamide (Ifex) was found to be superior for treating recurrent and primary refractory…
The use of trastuzumab deruxtecan (Enhertu), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared…
The use of panitumumab (Vectibix) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic…
The use of autologous stem cell transplant (ASCT) early in the course of treatment showed…
Peter Mac’s Associate Professor Michael Dickinson has presented new data from a trial of the…
Bishal Gyawali, Queen’s University, Ontario Where should investment be made today in order to save…